Brief: Compass Pathways Announces Dosing Complete For All Participants In Part A Of Phase 3 Comp005 Trial Of Comp360 Psilocybin
22/04/2025 11:03
April 22 (Reuters) - Compass Pathways PLC CMPS.O: COMPASS PATHWAYS ANNOUNCES DOSING COMPLETE FOR ALL PARTICIPANTS IN PART A OF PHASE 3 COMP005 TRIAL OF COMP360 PSILOCYBIN FOR TREATMENT-RESISTANT DEPRESSION COMPASS PATHWAYS PLC - TOP-LINE 6-WEEK PRIMARY ENDPOINT RESULTS EXPECTED IN LATE JUNE Source text: ID:nBw31H0b6a Further company coverage: CMPS.O
Recent news on COMPASS Pathways
See all newsBrief: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Trump's psychedelic drug order boosts investor interest with promise of faster reviews
UK's Compass Pathways Q1 operating income beats estimates as expenses fall
Health Rounds: Researchers gain new insight into how psychedelics affect the brain
U.S. STOCKS ON THE MOVE-Eli Lilly, Compass Pathways, Charter Communications